STX1A
Basic information
Region (hg38): 7:73699206-73719672
Previous symbols: [ "STX1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- Autism;Intellectual disability (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the STX1A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 7 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 2 | 2 | ||||
non coding | 1 | |||||
Total | 1 | 5 | 4 | 5 | 1 |
Variants in STX1A
This is a list of pathogenic ClinVar variants found in the STX1A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-73700443-G-A | STX1A-related disorder | Likely benign (May 28, 2019) | ||
7-73700463-AGAT-A | Uncertain significance (Jun 01, 2024) | |||
7-73700490-T-C | Likely benign (Jul 21, 2018) | |||
7-73700734-C-T | Uncertain significance (Mar 01, 2023) | |||
7-73700778-G-A | Inborn genetic diseases | Likely benign (Aug 01, 2024) | ||
7-73700794-TCTA-T | Autism;Intellectual disability | Likely pathogenic (Apr 22, 2022) | ||
7-73700799-C-T | Inborn genetic diseases | Likely benign (Nov 11, 2024) | ||
7-73702674-G-A | Likely benign (Apr 01, 2023) | |||
7-73702846-T-C | Intellectual disability;Seizure | Likely pathogenic (Apr 22, 2022) | ||
7-73702852-TCCA-T | Autism;Intellectual disability | Likely pathogenic (Apr 22, 2022) | ||
7-73702969-G-C | Intellectual disability;Seizure | Likely pathogenic (Apr 22, 2022) | ||
7-73702979-T-C | Inborn genetic diseases | Uncertain significance (Feb 10, 2022) | ||
7-73704179-G-C | Neurodevelopmental abnormality • Seizure;Intellectual disability | Likely pathogenic (Apr 22, 2022) | ||
7-73704365-C-T | Likely benign (Aug 13, 2018) | |||
7-73704407-G-A | STX1A-related disorder | Likely benign (Jan 27, 2020) | ||
7-73704424-C-T | Autism;Intellectual disability | Pathogenic (Apr 22, 2022) | ||
7-73705197-A-C | Intellectual disability;Seizure | Uncertain significance (Apr 22, 2022) | ||
7-73708629-C-T | Likely benign (Feb 01, 2024) | |||
7-73708647-G-A | STX1A-related disorder | Benign (Dec 09, 2019) | ||
7-73708672-C-G | Inborn genetic diseases | Uncertain significance (May 09, 2024) | ||
7-73709038-C-A | STX1A-related disorder | Likely benign (Aug 13, 2019) | ||
7-73709092-C-T | Inborn genetic diseases | Likely benign (Oct 07, 2024) | ||
7-73719606-C-T | Inborn genetic diseases | Uncertain significance (Jan 13, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
STX1A | protein_coding | protein_coding | ENST00000222812 | 10 | 20467 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.979 | 0.0215 | 125719 | 0 | 3 | 125722 | 0.0000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.40 | 98 | 191 | 0.512 | 0.0000123 | 1930 |
Missense in Polyphen | 23 | 67.253 | 0.34199 | 621 | ||
Synonymous | 0.950 | 66 | 76.6 | 0.862 | 0.00000555 | 507 |
Loss of Function | 3.50 | 1 | 16.2 | 0.0618 | 8.35e-7 | 194 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000291 | 0.0000291 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000176 | 0.0000176 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in hormone and neurotransmitter exocytosis (By similarity). Potentially involved in docking of synaptic vesicles at presynaptic active zones. May mediate Ca(2+)- regulation of exocytosis acrosomal reaction in sperm. {ECO:0000250|UniProtKB:P32851}.;
- Disease
- DISEASE: Note=STX1A is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region. {ECO:0000305|PubMed:9311751}.;
- Pathway
- Synaptic vesicle cycle - Homo sapiens (human);SNARE interactions in vesicular transport - Homo sapiens (human);Amphetamine addiction - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics;Serotonin Transporter Activity;Synaptic Vesicle Pathway;Monoamine Transport;Developmental Biology;Disease;Other interleukin signaling;Signaling by Interleukins;Cytokine Signaling in Immune system;Effects of Botulinum toxin;Toxicity of botulinum toxin type C (BoNT/C);Uptake and actions of bacterial toxins;Neurotoxicity of clostridium toxins;Infectious disease;Immune System;Neuronal System;Glutamate Neurotransmitter Release Cycle;Dopamine Neurotransmitter Release Cycle;Acetylcholine Neurotransmitter Release Cycle;GABA synthesis, release, reuptake and degradation;Neurotransmitter release cycle;Neurexins and neuroligins;Transmission across Chemical Synapses;Protein-protein interactions at synapses;Serotonin Neurotransmitter Release Cycle;Norepinephrine Neurotransmitter Release Cycle;LGI-ADAM interactions
(Consensus)
Recessive Scores
- pRec
- 0.438
Intolerance Scores
- loftool
- 0.298
- rvis_EVS
- -0.36
- rvis_percentile_EVS
- 28.63
Haploinsufficiency Scores
- pHI
- 0.479
- hipred
- Y
- hipred_score
- 0.853
- ghis
- 0.548
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.722
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Stx1a
- Phenotype
- embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- positive regulation of neurotransmitter secretion;intracellular protein transport;exocytosis;vesicle fusion;response to gravity;positive regulation of norepinephrine secretion;regulation of synaptic vesicle priming;synaptic vesicle docking;cytokine-mediated signaling pathway;synaptic vesicle fusion to presynaptic active zone membrane;secretion by cell;positive regulation of catecholamine secretion;SNARE complex assembly;positive regulation of calcium ion-dependent exocytosis;vesicle docking;regulation of insulin secretion;protein localization to membrane;positive regulation of excitatory postsynaptic potential
- Cellular component
- extracellular region;cytosol;plasma membrane;synaptic vesicle;voltage-gated potassium channel complex;endomembrane system;postsynaptic density;integral component of membrane;cell junction;secretory granule;integral component of synaptic vesicle membrane;axon;SNARE complex;nuclear membrane;actomyosin;presynaptic membrane;neuron projection;presynaptic active zone membrane;synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex;synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex;synaptobrevin 2-SNAP-25-syntaxin-1a complex;glutamatergic synapse;integral component of presynaptic membrane
- Molecular function
- SNARE binding;SNAP receptor activity;protein binding;calcium channel inhibitor activity;chloride channel inhibitor activity;kinase binding;protein domain specific binding;protein binding, bridging;myosin head/neck binding;ATP-dependent protein binding;ion channel binding;protein heterodimerization activity;protein N-terminus binding;calcium-dependent protein binding